Korean J Gynecol Oncol Colposc.  1997 Dec;8(4):388-394.

A Clinical Study on the Effect and Toxicity of rhGM-CSF

• Saw HS
• Lee JK
• Lee YH
• Lee SH
• Sunwoo TW
• Park JH
• Kim SK
• Lee KJ
• Hur JY
• Park YK
• Ju KS
• Chough SY

Abstract

Dosage reinforcement of chemotherapeutic agent is thought to be a solution in treating many malignancies, including ovarian cancer and cervical cancer. The remission rate after administration of chemotherapeutic agents has a positive correlation with dosage and in cases where limitations were put on dosage, improved survival rate was achieved with dose-intensive therapy facilitated by autologous bone marrow transplantation(BMT) or the use of cytokines such as G-CSF. Our objectives are to evaluate therapeutic efficacy and toxicity of GM-CSF and to elucidate the effect of premedication which was administered to minimize the toxicity of the GM-CSF. Total number of patients entered into this study was fifty two and they are consisted of thirty seven patients of the uterine cervix, fourteen patients of ovarian cancer and one endometrial cancer patient. The increase in neutrophil count and WBC count was found to be statistically valid, but the changes in the number of platelets, hemoglobin, neutrophil and monocytes were not shown to be meaningful when statistics are brought in. Administration of GM-CSF resulted in mild toxicities such as myalgia, fever, skin reaction and neuropathy. But, one patient had grade 3 myalgia. Premedication brought about meaningful reductions in the toxicities of GM-CSF and can be used safely to reduce the toxicities.

Keyword

RhGM-CSF; Therapeutic efficacy; Toxicity; Premedication

MeSH Terms

Bone Marrow
Cervix Uteri
Cytokines
Endometrial Neoplasms
Female
Fever
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Humans
Monocytes
Myalgia
Neutrophils
Ovarian Neoplasms
Premedication
Skin
Survival Rate
Uterine Cervical Neoplasms
Cytokines
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor